Literature DB >> 20837658

Glioma oncoprotein Bcl2L12 inhibits the p53 tumor suppressor.

Alexander H Stegh1, Cameron Brennan, John A Mahoney, Kristin L Forloney, Harry T Jenq, Janina P Luciano, Alexei Protopopov, Lynda Chin, Ronald A Depinho.   

Abstract

Glioblastoma multiforme (GBM) is a lethal brain tumor characterized by intense apoptosis resistance and extensive necrosis. Bcl2L12 (for Bcl2-like 12) is a cytoplasmic and nuclear protein that is overexpressed in primary GBM and functions to inhibit post-mitochondrial apoptosis signaling. Here, we show that nuclear Bcl2L12 physically and functionally interacts with the p53 tumor suppressor, as evidenced by the capacity of Bcl2L12 to (1) enable bypass of replicative senescence without concomitant loss of p53 or p19 (Arf), (2) inhibit p53-dependent DNA damage-induced apoptosis, (3) impede the capacity of p53 to bind some of its target gene promoters, and (4) attenuate endogenous p53-directed transcriptomic changes following genotoxic stress. Correspondingly, The Cancer Genome Atlas profile and tissue protein analyses of human GBM specimens show significantly lower Bcl2L12 expression in the setting of genetic p53 pathway inactivation. Thus, Bcl2L12 is a multifunctional protein that contributes to intense therapeutic resistance of GBM through its ability to operate on two key nodes of cytoplasmic and nuclear signaling cascades.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20837658      PMCID: PMC2947771          DOI: 10.1101/gad.1924710

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  74 in total

1.  p53 has a direct apoptogenic role at the mitochondria.

Authors:  Motohiro Mihara; Susan Erster; Alexander Zaika; Oleksi Petrenko; Thomas Chittenden; Petr Pancoska; Ute M Moll
Journal:  Mol Cell       Date:  2003-03       Impact factor: 17.970

2.  The p53MH algorithm and its application in detecting p53-responsive genes.

Authors:  J Hoh; S Jin; T Parrado; J Edington; A J Levine; J Ott
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-19       Impact factor: 11.205

3.  Puma is an essential mediator of p53-dependent and -independent apoptotic pathways.

Authors:  John R Jeffers; Evan Parganas; Youngsoo Lee; Chunying Yang; JinLing Wang; Jennifer Brennan; Kirsteen H MacLean; Jiawen Han; Thomas Chittenden; James N Ihle; Peter J McKinnon; John L Cleveland; Gerard P Zambetti
Journal:  Cancer Cell       Date:  2003-10       Impact factor: 31.743

4.  Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis.

Authors:  Jerry E Chipuk; Tomomi Kuwana; Lisa Bouchier-Hayes; Nathalie M Droin; Donald D Newmeyer; Martin Schuler; Douglas R Green
Journal:  Science       Date:  2004-02-13       Impact factor: 47.728

5.  Staurosporine-induced apoptosis is independent of p16 and p21 and achieved via arrest at G2/M and at G1 in U251MG human glioma cell line.

Authors:  Fumiyuki Yamasaki; Seiji Hama; Hiroyuki Yoshioka; Yoshinori Kajiwara; Kaita Yahara; Kazuhiko Sugiyama; Yuji Heike; Kazunori Arita; Kaoru Kurisu
Journal:  Cancer Chemother Pharmacol       Date:  2003-03-20       Impact factor: 3.333

6.  p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa.

Authors:  Andreas Villunger; Ewa M Michalak; Leigh Coultas; Franziska Müllauer; Gunther Böck; Michael J Ausserlechner; Jerry M Adams; Andreas Strasser
Journal:  Science       Date:  2003-09-18       Impact factor: 47.728

7.  HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53.

Authors:  Laëtitia K Linares; Arnd Hengstermann; Aaron Ciechanover; Stefan Müller; Martin Scheffner
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-24       Impact factor: 11.205

8.  Defining the p53 DNA-binding domain/Bcl-x(L)-binding interface using NMR.

Authors:  Andrew M Petros; Angelo Gunasekera; Nan Xu; Edward T Olejniczak; Stephen W Fesik
Journal:  FEBS Lett       Date:  2004-02-13       Impact factor: 4.124

9.  Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis.

Authors:  Robert M Bachoo; Elizabeth A Maher; Keith L Ligon; Norman E Sharpless; Suzanne S Chan; Mingjian James You; Yi Tang; Jessica DeFrances; Elizabeth Stover; Ralph Weissleder; David H Rowitch; David N Louis; Ronald A DePinho
Journal:  Cancer Cell       Date:  2002-04       Impact factor: 31.743

Review 10.  The molecular and genetic basis of neurological tumours.

Authors:  Yuan Zhu; Luis F Parada
Journal:  Nat Rev Cancer       Date:  2002-08       Impact factor: 60.716

View more
  40 in total

Review 1.  Studying a complex tumor: potential and pitfalls.

Authors:  Siyuan Zheng; Milan G Chheda; Roel G W Verhaak
Journal:  Cancer J       Date:  2012 Jan-Feb       Impact factor: 3.360

2.  Whole-genome sequencing identifies a recurrent functional synonymous mutation in melanoma.

Authors:  Jared J Gartner; Stephen C J Parker; Todd D Prickett; Ken Dutton-Regester; Michael L Stitzel; Jimmy C Lin; Sean Davis; Vijaya L Simhadri; Sujata Jha; Nobuko Katagiri; Valer Gotea; Jamie K Teer; Xiaomu Wei; Mario A Morken; Umesh K Bhanot; Guo Chen; Laura L Elnitski; Michael A Davies; Jeffrey E Gershenwald; Hannah Carter; Rachel Karchin; William Robinson; Steven Robinson; Steven A Rosenberg; Francis S Collins; Giovanni Parmigiani; Anton A Komar; Chava Kimchi-Sarfaty; Nicholas K Hayward; Elliott H Margulies; Yardena Samuels
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-30       Impact factor: 11.205

3.  Spherical nucleic acid nanoparticle conjugates as an RNAi-based therapy for glioblastoma.

Authors:  Samuel A Jensen; Emily S Day; Caroline H Ko; Lisa A Hurley; Janina P Luciano; Fotini M Kouri; Timothy J Merkel; Andrea J Luthi; Pinal C Patel; Joshua I Cutler; Weston L Daniel; Alexander W Scott; Matthew W Rotz; Thomas J Meade; David A Giljohann; Chad A Mirkin; Alexander H Stegh
Journal:  Sci Transl Med       Date:  2013-10-30       Impact factor: 17.956

4.  The novel member of the BCL2 gene family, BCL2L12, is substantially elevated in chronic lymphocytic leukemia patients, supporting its value as a significant biomarker.

Authors:  Sotirios G Papageorgiou; Christos K Kontos; Vassiliki Pappa; Hellinida Thomadaki; Frida Kontsioti; John Dervenoulas; Efstathios Papageorgiou; Theofanis Economopoulos; Andreas Scorilas
Journal:  Oncologist       Date:  2011-07-07

Review 5.  Beyond effector caspase inhibition: Bcl2L12 neutralizes p53 signaling in glioblastoma.

Authors:  Alexander H Stegh; Ronald A DePinho
Journal:  Cell Cycle       Date:  2011-01-01       Impact factor: 4.534

6.  Estrogen receptor β isoform 5 confers sensitivity of breast cancer cell lines to chemotherapeutic agent-induced apoptosis through interaction with Bcl2L12.

Authors:  Ming-Tsung Lee; Shuk-Mei Ho; Pheruza Tarapore; Irving Chung; Yuet-Kin Leung
Journal:  Neoplasia       Date:  2013-11       Impact factor: 5.715

7.  Effect of doxorubicin, oxaliplatin, and methotrexate administration on the transcriptional activity of BCL-2 family gene members in stomach cancer cells.

Authors:  Dimitra Florou; Christos Patsis; Alexandros Ardavanis; Andreas Scorilas
Journal:  Cancer Biol Ther       Date:  2013-05-10       Impact factor: 4.742

8.  Stress Hormone Cortisol Enhances Bcl2 Like-12 Expression to Inhibit p53 in Hepatocellular Carcinoma Cells.

Authors:  Weizhong Wu; Sanguang Liu; Yunfei Liang; Zegao Zhou; Wei Bian; Xueqing Liu
Journal:  Dig Dis Sci       Date:  2017-10-17       Impact factor: 3.199

Review 9.  Gene therapy for brain tumors: basic developments and clinical implementation.

Authors:  Hikmat Assi; Marianela Candolfi; Gregory Baker; Yohei Mineharu; Pedro R Lowenstein; Maria G Castro
Journal:  Neurosci Lett       Date:  2012-08-10       Impact factor: 3.046

10.  Cisplatin downregulates BCL2L12, a novel apoptosis-related gene, in glioblastoma cells.

Authors:  Mahdieh Sadat Taghavi; Azim Akbarzadeh; Reza Mahdian; Kayhan Azadmanesh; Gholamreza Javadi
Journal:  In Vitro Cell Dev Biol Anim       Date:  2013-05-25       Impact factor: 2.416

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.